A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

View at publisher Summarise with VIRAT
Authors: Jennifer Croden, G. García-Manero, K. S. Chien, C. DiNardo, G. Borthakur, D. Hammond, P. Bose, Nicholas James Short, L. Romero, H. Shneider, M.D. Hatfield, S. Pierce
+3 more X. Huang, Hyunsoo Hwang, Guillermo Montalban Bravo
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are commonly managed with erythropoiesis-stimulating agents, luspatercept, or hypomethylating agents. Despite this, the disease often becomes refractory and patients develop transfusion dependence. Preclinical evidence suggests that targeting innate immune signaling, including NF-kB activation, may improve hematopoiesis. Fostamatinib, an oral SYK inhibitor approved for immune thrombocytopenia, was evaluated in a phase 1 open-label study in previously treated lower-risk MDS/CMML. Eleven patients received fostamatinib starting at 100 mg twice daily with dose escalation for lack of response. Patients had received a median of 3 prior therapies and most were transfusion-dependent. Over a median of 5 treatment cycles and 14.4 months of follow-up, no objective responses were observed, although all patients achieved stable disease. Transfusion needs remained largely unchanged. There were no dose-limiting toxicities. Although safe, fostamatinib demonstrated no clinical benefit, underscoring the need for alternative strategies to modulate inflammatory signaling in MDS/CMML.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Hematological disorders and diagnostics Hematopoietic Stem Cell Transplantation

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Volume
67
Issue
7
Pages
1580–1586
Publication date
30 March 2026
Language
EN